Quick Answer
USANA HEALTH SCIENCES INC reported Revenue From Contract With Customer Excluding Assessed Tax of $925.26 million for the year ending 2025.
- USANA HEALTH SCIENCES INC showed an increase of +8.3% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from USANA HEALTH SCIENCES INC's annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $266.62 million | Q2 2020: $258.99 million | Q3 2020: $298.51 million | Q1 2021: $307.98 million | Q2 2021: $336.84 million | Q3 2021: $274.35 million | Q1 2022: $272.87 million | Q2 2022: $264.47 million | Q3 2022: $233.30 million | Q1 2023: $248.36 million | Q2 2023: $238.20 million | Q3 2023: $213.37 million | Q1 2024: $227.80 million | Q2 2024: $212.87 million | Q3 2024: $200.22 million | Q1 2025: $249.54 million | Q2 2025: $235.85 million | Q3 2025: $213.67 million.
- Over the full 8 years of available data (2018 to 2025), USANA HEALTH SCIENCES INC's Revenue From Contract With Customer Excluding Assessed Tax has declined by 22.2%.
- Historical annual values: Fiscal year 2025: $925.26 million | Fiscal year 2024: $854.50 million | Fiscal year 2023: $921.01 million | Fiscal year 2022: $998.60 million | Fiscal year 2021: $1.19 billion | Fiscal year 2020: $1.13 billion | Fiscal year 2019: $1.06 billion | Fiscal year 2018: $1.19 billion.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: